NKTR-102 Phase 2 Clinical Data Accepted for Oral Presentation at 2010 ASCO... -- SAN CARLOS, Calif., May 20 /PRNewswire-FirstCall/ --

Nektar To Host Investor Breakfast at ASCO on Monday, June 7, 2010

Nektar will also webcast a presentation to investors and analysts to be held at the 2010 ASCO Meeting on Monday, June 7, 2010 at 8 AM Central Time.

Panelists at the investor event will include:

* Ignace Vergote, M.D., Ph.D., Head of the Department of Obstetrics and Gynaecology and Gynaecologic Oncology at the Catholic University of Leuven, Belgium;
* Robert Coleman, M.D., Director of Clinical Research, Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; and
* Daniel Von Hoff, M.D., F.A.C.P., Chief Scientific Officer, TGen Clinical Research Services at Scottsdale Healthcare and U.S. Oncology, and Clinical Professor of Medicine at the University of Arizona College of Medicine and 2010 recipient of the ASCO David A. Karnofsky Memorial Award Lecture.


The event will be accessible live and by replay and can be accessed from the homepage of the company's website at www.nektar.com beginning on June 7, 2010 at 8:00 AM Central Time.

podcast: CA-125 Change Over Time Shows Promise as Screening Tool for Early Detection of Ovarian Cancer

CA-125 Change Over Time Shows Promise as Screening Tool for Early Detection of Ovarian Cancer

Blood test currently approved to find recurrence full of new possibility; invasive, high-grade disease uncovered at curable stage
MD Anderson News Release 05/20/10

PODCAST: Listen as Dr. Lu and
Dr. Bast speak about a new screening
tool to detect ovarian cancer.

Genetic/Familial High-Risk Assessment: Breast and Ovarian — J Natl Compr Canc Network NCCN

Note: full free access; includes risks of Li-Fraumeni, Cowden and Lynch Syndromes

PLoS ONE: Repertoire of microRNAs in Epithelial Ovarian Cancer as Determined by Next Generation Sequencing of Small RNA cDNA Libraries

Note: full free access / technical

Background

MicroRNAs (miRNAs) are small regulatory RNAs that are implicated in cancer pathogenesis and have recently shown promise as blood-based biomarkers for cancer detection. Epithelial ovarian cancer is a deadly disease for which improved outcomes could be achieved by successful early detection and enhanced understanding of molecular pathogenesis that leads to improved therapies. A critical step toward these goals is to establish a comprehensive view of miRNAs expressed in epithelial ovarian cancer tissues as well as in normal ovarian surface epithelial cells.

Conclusions

This report expands the body of miRNAs known to be expressed in epithelial ovarian cancer and provides a useful resource for future studies of the role of miRNAs in the pathogenesis and early detection of ovarian cancer.

Discussion

The work reported here was motivated by the hypothesis that the entire repertoire of miRNAs expressed in ovarian cancer, including potentially tissue- and cancer-specific miRNAs, had not yet been elucidated.

Rebuttal of "Flawed Experimental Design Reveals the Need for Guidelines Requiring Appropriate Positive Controls in Endocrine Disruption Research"

Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: Pooled analysis in five studies within the Ovarian Cancer Association Consortium

"This pooled analysis provides further evidence that the VDR rs2228570 polymorphism might influence ovarian cancer susceptibility."

(U.S.) Do Insurers Have to Pay for Colonoscopy Now? - Prescriptions Blog - NYTimes.com

Clinical Care Options database - inPractice

Note: no sign on required/searchable database
Jointly sponsored by USF Health and Clinical Care Options, LLC:
Use inPractice’s search to quickly access answers to your point-of-care questions. inPractice searches the following resources at the same time:

• HIV inPractice
• Oncology inPractice
• Drug Information

• Guidelines
• PubMed
• CCO CME/CE

Seth's Blog: Multiple dumbnesses

Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer.

CONCLUSION:
Secondary cytoreduction in relapsed ovarian cancer is safe and feasible and perioperative outcome is not inferior compared to primary cytoreduction. Surgery-associated morbidity should represent a minor aspect in the selection and counselling of patients regarding treatment options for recurrent ovarian cancer.

AJR Am J Roentgenol. 2010 Role of PET/CT in Ovarian Cancer

Abstract OBJECTIVE: The purpose of this article is to review the role of FDG PET/CT in ovarian cancer, which is the leading cause of death among gynecologic cancers. CONCLUSION: FDG PET/CT can significantly modify the assessment of the extent of primary and recurrent ovarian cancer and, hence, often alters patient management substantially. FDG PET/CT has thus become a critical tool for the preoperative evaluation of women with primary ovarian cancer and for postoperative follow-up assessment for evidence of recurrence in these patients.

A Longitudinal Investigation of Psychological Disorders in Patients Prior and Subsequent to a Diagnosis of Ovarian Cancer

Pre-counseling Education for Low Literacy Women at Risk of Hereditary Breast and Ovarian Cancer (HBOC): Patient Experiences Using the Cancer Risk...

Pre-counseling Education for Low Literacy Women at Risk of Hereditary Breast and Ovarian Cancer (HBOC): Patient Experiences Using the Cancer Risk Education Intervention Tool (CREdIT)